TitleGain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector.
Publication TypeJournal Article
Year of Publication2018
AuthorsWang C, Najm R, Xu Q, Jeong D-E, Walker D, Balestra ME, Yoon SYeon, Yuan H, Li G, Miller ZA, Miller BL, Malloy MJ, Huang Y
JournalNat Med
Volume24
Issue5
Pagination647-657
Date Published2018 May
ISSN1546-170X
Abstract

Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems. Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-β (Aβ) peptides, and that they displayed GABAergic neuron degeneration. ApoE4 increased Aβ production in human, but not in mouse, neurons. Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4. Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4. Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.

DOI10.1038/s41591-018-0004-z
Alternate JournalNat. Med.
PubMed ID29632371
PubMed Central IDPMC5948154
Grant ListP50 AG023501 / AG / NIA NIH HHS / United States
R01 AG048017 / AG / NIA NIH HHS / United States
R01 AG056305 / AG / NIA NIH HHS / United States
RF1 AG048030 / AG / NIA NIH HHS / United States